Frontlight ResearchEarly access
Taking people in New ZealandEarly phase 1
Imaging study of RYZ512 in people with metastatic kidney cancer
Tests the imaging agent RYZ512 in adults with spread clear cell kidney cancer.
Key facts
- Who runs it
- RayzeBio, Inc.
- Where
- Christchurch, New ZealandSee the siteAlso in 2 other countries, 5 sites
- Trial code
- Registry title
- Imaging Study in Metastatic Clear Cell RCC.
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 10 people, planned
- Started
- 15 Jun 2026
- Expected to end
- Feb 2027
- Type of study
- Interventional
- Treatments tested
- RYZ512
- Record updated
- 13 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose metastatic clear cell kidney cancer has been confirmed by biopsy. It studies an imaging agent, RYZ512.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Metastatic clear cell renal cell carcinoma (kidney cancer that has spread), proven by biopsy.
- Earlier treatment
- People taking certain medicines that cannot be stopped 5 half-lives before RYZ512 and cannot be restarted until all study imaging is done cannot join.
Main reasons for not taking part
- Taking anticonvulsants, antipsychotics, carbonic anhydrase inhibitors, COX-2 inhibitors, sulfatase inhibitors or sulfonamides that cannot be stopped 5 half-lives before RYZ512 and cannot be restarted until all study imaging is done
- Women who could have children and are pregnant or breastfeeding
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- At least 18 years old at the time of signing the informed consent form (ICF)
- Biopsy proven metastatic clear cell renal cell carcinoma (RCC)
Who cannot take part
- Subjects taking below mentioned medications that cannot be stopped 5 half-lives prior to RYZ512 administration and cannot be restarted until all study-related imaging is completed: Anticonvulsants, Antipsychotics, Carbonic Anhydrase inhibitors, COX-2 Inhibitors, Sulfatase Inhibitors, Sulfonamides
- Women of Childbearing Potential that are pregnant or breastfeeding; Note: Additional criteria may apply and will be assessed by the study site
This trial is currently available in New Zealand.
Also in 2 other countries, 5 sites
- ChristchurchHospital not named in the registryContact: RayzeBio Clinical TrialsTaking people
About the trial
What the trial wants to find out
This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in Subjects with Metastatic Clear Cell Renal Cell Cancer (RCC).
The group in the trial
- Imaging Study in Metastatic Clear Cell RCC.Treatment being tested
Treatment: RYZ512
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 0 Imaging Study to Assess the Feasibility, Biodistribution, and Dosimetry of the Imaging Agent in Subjects With Metastatic Clear Cell Renal Cell Cancer (RCC).
- Plain-language title
- Imaging study of RYZ512 in people with metastatic kidney cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 13 October 2026